MedTech Co seeks to optimize its product portfolio amid declining profitability. The case presents five product lines with varying financial performance and market dynamics. Candidates must analyze profitability metrics, assess market attractiveness and competitive positioning, and recommend which lines to grow, maintain, or exit.
Key Insights:
- Profitability alone is insufficient for portfolio decisions—must consider market growth, market share position, and strategic fit
- High-margin products (Diagnostic Imaging at 50%, Surgical Tools at 37.5%) warrant continued investment, while unprofitable lines (Lab Equipment at 0%) may require exit
- Recurring revenue models (bundled services) offer superior long-term value compared to transactional models, influencing retention strategies
- Fixed cost allocation is critical—lines with high fixed costs relative to revenue (Lab Equipment) are particularly vulnerable to market downturns